139 related articles for article (PubMed ID: 32723677)
1. Women who develop ovarian cancer show an increase in serum calcium and a decrease in serum albumin. A longitudinal study in the Janus Serum Bank Cohort.
Schwartz GG; Tretli S; Klug MG; Robsahm TE
Gynecol Oncol; 2020 Oct; 159(1):264-269. PubMed ID: 32723677
[TBL] [Abstract][Full Text] [Related]
2. Prediagnostic serum calcium and albumin and ovarian cancer: A nested case-control study in the Norwegian Janus Serum Bank Cohort.
Schwartz GG; Tretli S; Vos L; Robsahm TE
Cancer Epidemiol; 2017 Aug; 49():225-230. PubMed ID: 28732327
[TBL] [Abstract][Full Text] [Related]
3. Serum Calcium and Serum Albumin Are Biomarkers That Can Discriminate Malignant from Benign Pelvic Masses.
Kelly MG; Winkler SS; Lentz SS; Berliner SH; Swain MF; Skinner HG; Schwartz GG
Cancer Epidemiol Biomarkers Prev; 2015 Oct; 24(10):1593-8. PubMed ID: 26184501
[TBL] [Abstract][Full Text] [Related]
4. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer.
Simmons AR; Fourkala EO; Gentry-Maharaj A; Ryan A; Sutton MN; Baggerly K; Zheng H; Lu KH; Jacobs I; Skates S; Menon U; Bast RC
Cancer Prev Res (Phila); 2019 Jun; 12(6):391-400. PubMed ID: 30967390
[TBL] [Abstract][Full Text] [Related]
5. HE4 as an Early Detection Biomarker of Epithelial Ovarian Cancer: Investigations in Prediagnostic Specimens From the Janus Serumbank.
Gislefoss RE; Langseth H; Bolstad N; Nustad K; Mørkrid L
Int J Gynecol Cancer; 2015 Nov; 25(9):1608-15. PubMed ID: 26501436
[TBL] [Abstract][Full Text] [Related]
6. The JANUS serum bank.
Jellum E; Andersen A; Lund-Larsen P; Theodorsen L; Orjasaeter H
Sci Total Environ; 1993 Nov; 139-140():527-35. PubMed ID: 8272856
[TBL] [Abstract][Full Text] [Related]
7. Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer.
Singh A; Gupta S; Badarukhiya JA; Sachan M
Int J Cancer; 2020 Sep; 147(6):1740-1752. PubMed ID: 32191343
[TBL] [Abstract][Full Text] [Related]
8. Y-box protein-1/p18 as novel serum marker for ovarian cancer diagnosis: A study by the Tumor Bank Ovarian Cancer (TOC).
Rohr I; Braicu EI; En-Nia A; Heinrich M; Richter R; Chekerov R; Dechend R; Heidecke H; Dragun D; Schäfer R; Gorny X; Lindquist JA; Brandt S; Sehouli J; Mertens PR
Cytokine; 2016 Sep; 85():157-64. PubMed ID: 27371774
[TBL] [Abstract][Full Text] [Related]
9. A novel algorithm to improve specificity in ovarian cancer detection.
Arjomandi A; Delanoy ML; Walker RP; Binder SR
Cancer Treat Res Commun; 2018; 15():32-35. PubMed ID: 30207285
[TBL] [Abstract][Full Text] [Related]
10. A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care.
Shadfan BH; Simmons AR; Simmons GW; Ho A; Wong J; Lu KH; Bast RC; McDevitt JT
Cancer Prev Res (Phila); 2015 Jan; 8(1):37-48. PubMed ID: 25388014
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.
Hurley LC; Levin NK; Chatterjee M; Coles J; Muszkat S; Howarth Z; Dyson G; Tainsky MA
Cancer Biomark; 2020; 27(3):407-421. PubMed ID: 32083570
[TBL] [Abstract][Full Text] [Related]
12. Computer assisted optical screening of human ovarian cancer using Raman spectroscopy.
Ullah I; Ahmad I; Nisar H; Khan S; Ullah R; Rashid R; Mahmood H
Photodiagnosis Photodyn Ther; 2016 Sep; 15():94-9. PubMed ID: 27238739
[TBL] [Abstract][Full Text] [Related]
13. Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer.
Schummer M; Thorpe J; Giraldez MD; Bergan L; Tewari M; Urban N
PLoS One; 2015; 10(11):e0142911. PubMed ID: 26565788
[TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer screening: Current status and future directions.
Nash Z; Menon U
Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():32-45. PubMed ID: 32273169
[TBL] [Abstract][Full Text] [Related]
15. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma.
Diamandis EP; Scorilas A; Fracchioli S; Van Gramberen M; De Bruijn H; Henrik A; Soosaipillai A; Grass L; Yousef GM; Stenman UH; Massobrio M; Van Der Zee AG; Vergote I; Katsaros D
J Clin Oncol; 2003 Mar; 21(6):1035-43. PubMed ID: 12637468
[TBL] [Abstract][Full Text] [Related]
16. Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations.
Lentz SE; Powell CB; Haque R; Armstrong MA; Anderson M; Liu Y; Jiang W; Chillemi G; Shaw S; Alvarado MM; Kushi LH; Skates SJ
Gynecol Oncol; 2020 Dec; 159(3):804-810. PubMed ID: 33012551
[TBL] [Abstract][Full Text] [Related]
17. Early stage detection and screening of ovarian cancer: A research opportunity and significant challenge for biosensor technology.
Franier B; Thompson M
Biosens Bioelectron; 2019 Jun; 135():71-81. PubMed ID: 31003031
[TBL] [Abstract][Full Text] [Related]
18. Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
Huang J; Mondul AM; Weinstein SJ; Koutros S; Derkach A; Karoly E; Sampson JN; Moore SC; Berndt SI; Albanes D
Br J Cancer; 2016 Oct; 115(9):1087-1095. PubMed ID: 27673363
[TBL] [Abstract][Full Text] [Related]
19. A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.
Russell MR; Graham C; D'Amato A; Gentry-Maharaj A; Ryan A; Kalsi JK; Ainley C; Whetton AD; Menon U; Jacobs I; Graham RLJ
Br J Cancer; 2017 Aug; 117(5):666-674. PubMed ID: 28664912
[TBL] [Abstract][Full Text] [Related]
20. Prospective studies of total and ionized serum calcium in relation to incident and fatal ovarian cancer.
Schwartz GG; Skinner HG
Gynecol Oncol; 2013 Apr; 129(1):169-72. PubMed ID: 23313738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
